VIKING THERAPEUTICS IRELAND LIMITED

Overview

Viking Therapeutics Ireland Limited is a biopharmaceutical company based in Ireland, focused on developing novel therapeutics for metabolic and endocrine disorders. The company is advancing clinical programs centered on VK2735, a dual agonist of GLP-1 and GIP receptors, with a Phase 3 obesity program involving two clinical trials, VANQUISH-1 and VANQUISH-2. Data from earlier Phase 1 and 2 trials indicate positive safety, tolerability, and clinical benefit signals. The company is also evaluating an oral formulation of VK2735 for obesity. Additionally, Viking is developing VK2809, an orally available small molecule targeting thyroid hormone receptor beta for lipid and metabolic disorders. The name suggests a focus on innovative drug development for metabolic conditions. Beyond registry-level identification, no further business details are publicly captured.

Location & registered address

6th Floor

2 Grand Canal Square

Dublin 2

Ireland

Industry classification

NACE Rev. 2 — 46.46

→ All NACE 46.46 companies in Ireland · In Dublin